Suicidal thoughts and behaviors.
Conditions
Interventions
Intervention 1: Intervention group: Those diagnosed with major depressive disorders who aside to their routine and standard treatment will receive a dose of 0.5mg/Kg of Es-Ketamine Hydrochloride from
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: This clinical trial study will be conducted in Ebne Sina and Hafez Hospital, Shiraz, Iran and all patients who are admitted to our medical care center during a one year period with complaints of suicidal ideas and with a diagnosis of DSM-5 major depressive disorder (MDD),
Exclusion criteria
Exclusion criteria: Those who have a positive history of alcohol or substance abuse during the past 6 months mood disorders due to any medical conditions pregnancy or lactation those with a positive history of ketamine abuse those with symptoms of psychosis unstable medical conditions with hypersensitivity to ketamine positive history of use of psychotropic agents or drugs like corticosteroids
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Suicidal thoughts and behaviors. Timepoint: Patients will be evaluated at baseline (8 hours before infusion), 24 hours, 7 and 10 days and two weeks after each infusions of Es-Ketamine or Midazolam in both groups. Method of measurement: The Beck Scale for Suicide Ideation (BSSI). | — |
Secondary
| Measure | Time frame |
|---|---|
| Es-Ketamine administration will reduce symptoms of patients with Major Depressive disorder 2weeks post infusion. Timepoint: before and 2 weeks after Es-Ketamine or Midazolam infusion. Method of measurement: Hamilton Rating Scale for Depression (HRSD). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactLaya Ahmadzade
Shiraz University of Medical Sciences
Outcome results
None listed